XXIII NIBIT MEETING

TRENTO

October
14-16, 2026

NIBIT BOARD

Paolo Ascierto, Napoli - IT
Matteo Bellone, Milano – IT
Vincenzo Bronte, Padova - IT
Giulia Casorati, Milano - IT
Mario Paolo Colombo, Milano - IT
Paola Nisticò, Roma - IT
Arsela Prelaj, Milano – IT
Maria Rescigno, Milano - IT
Antonio Sica, Milano - IT

NIBIT JUNIOR FACULTY

Beatrice Belmonte, Palermo - IT
Matteo Benelli, Firenze - IT
Lorenzo D'Ambrosio, Torino - IT
Roberto Ferrara, Milano - IT
Roberta Sommaggio, Padova - IT
Sheila Spada, Roma - IT
Marcella Tazzari, Meldola - IT

12:00 Registrations

13:45 Welcome addresses

SESSION 1. MYELOID CELLS IN CANCER
Chair:

14:00 Leila Akkari
Leiden University, Leiden, The Netherlands
From Diversity to Dependency:
Plasticity and State Evolution of Myeloid Cells in Cancer

14:20 Selected abstract

14:30 Sabina Sangaletti
Fondazione Istituto nazionale dei tumori, Milan, Italy
Shaping myeloid cell fate:
Bone marrow training in lung cancer-adapted myelopoiesis

14:50 Selected abstract

15:00 Selected abstract

15:10 Francesca Fallarino
University of Perugia, Perugia, Italy
Shaping tolerogenic trajectories in myeloid cells
through extracellular vesicles and immunometabolic networks

15:30 General discussion on the above topic

SESSION 2. IMMUNOMETABOLISM
Chair:

16:00 Teresa Manzo
University of Turin, Turin, Italy
Lipid-Based Control of Anti-Tumor Immunity

16:20 Selected abstract on Immunometabolism

16:30 Vincenzo Russo
Vita-Salute University, Milan, Italy
Metabolic interference in cancer immunotherapy

16:50	Selected abstract
17:00	Selected abstract
17:10	Roberta Zappasodi *Weill Cornell Medicine, New York, NY, USA* **Tumor metabolic control of anti-tumor immunity**
17:30	General Discussion
18:15	Poster Walk

SESSION 3. AI AND COMPUTATIONAL ONCOLOGY
Chair:

9:00 Mirea Crispin
University of Cambridge, Cambridge, UK
Data integration along the cancer continuum

9:20 Selected abstract

9:30 Selected abstract

9:40 Selected abstract

9:50 Francesca Demichelis
University of Trento, Trento, Italy
Plasma EV RNA and cancer patients' tumor microenvironment

10:10 General discussion

10:30 Coffee break

SESSION 4. NEURO-ONCO IMMUNOLOGY
Chair:

11:00 Moran Ami
University of Texas MD Anderson Cancer Center, Houston, TX USA
Nervous Cancers
How Nerves Shape the Tumor Immune Microenvironment

11:20 Selected abstract

11:30 Selected abstract

12:40 Selected abstract

11:50 Wolf Fridman
University of Paris/Cordeliers Research Centre, Paris, France
Neuro-cancer mimicry:
GABA modulates tumor immunity and impairs response to immunotherapy

12:10 General discussion

12:40 Lunch and poster walk

14.00 News from the Industry – Non CME Session

Pezcoller Keynote Lecture
Chair:

14.30 Enzo Galligioni
(Trento, Italy): the Pezcoller Foundation, Trento, Italy

14.40 Vinod Balachandran
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cold Yet Vaccinable? Vaccines for Pancreatic Cancer

SESSION 5. SOLVING THREE-DIMENSIONAL INTERACTIONS IN THE TUMOR MICROENVIRONMENT
Chair:

15:30 William Hwang
Harvard University, Boston, MD, USA
Spatial dissection of multicellular interactions in the pancreatic tumor microenvironment

15:50 3 Selected abstracts on Solving three-dimensional interactions in the tumor microenvironment

16:20 Denis Wirtz
Johns Hopkins University, Baltimore, PA, USA
3D mapping of solid tumors and new CAR-T therapies to resolve them

16:40 General discussion

17:10 Coffee break

Parmiani Keynote Lecture
Chair:

17:30 Samra Turajlic
Cancer Research UK Manchester Institute

Adjourn

SESSION 6. T AND B CELLS IN CANCER
Chair:

08:30 Christoph Bock
Medical University of Vienna, Vienna, Austria
Programmed Cells? Single-cell Biology and Cell Engineering for Immunity andCancer

08:50 Selected abstract

09:00 Selected abstract

09:10 Selected abstract

09:20 Enrico Lugli
Humanitas Research Hospital, Milan, Italy
Reinvigorating T cell function against solid tumors

09:40 General discussion

10:00 Coffee break

SESSION 7. MICROBIOTA
Chair:

10:30 Maria Rescigno
Humanitas Research Hospital, Milan, Italy
The microbiota in cancer treatment efficacy

10:50 Selected abstract

11:00 Selected abstract

11:10 Selected abstract

10:20 Nicola Segata
University of Trento, Trento, Italy
Metagenomics of the human microbiome: potential applications in oncology

11:40 General discussion

12:00	NIBIT Awards Nominations
12:30	Adjourn

VENUE

Grand Hotel Trento****
Piazza Dante 20
Trento

REGISTRATION FEES

Category	Regular Registration
NIBIT*/AIOM member over 35	€ 250,00 VAT included
NIBIT*/AIOM member under 35	€ 150,00 VAT included
NIBIT*/AIOM member Post Doc	€ 150,00 VAT included
NIBIT*/AIOM member PhD Student	€ 150,00 VAT included
NIBIT*/AIOM member Resident	€ 150,00 VAT included
Non member (all categories)**	€ 350,00 VAT included
Undergraduate student	Free of charge
Social dinner	€ 50,00 VAT included

*NIBIT member with settled payment of membership fee for 2025 and 2026
**Membership fee for 2026 is €50; to become a member please fill in the form here

C.M.E. ACCREDITATION

Provider: Achelois Srl – ID 7362

The Congress was granted 15 C.M.E. credits from the Italian Ministry of Health for the following specialties:

Physicians specialized in allergology and clinical immunology, pathological anatomy,clinical biochemistry, dermatology and venerology, hematology, oncology. Biologists.
Biomedical laboratory technician.

Obiettivo formativo: Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultra specialistica, ivi incluse le malattie rare e la medicina di genere (18)

HOW TO BECOME A NIBIT MEMBER

Becoming a NIBIT member is easy. Download the membership application form from www.nibit.org, fill it out completely, and send it via email t o segreteria@nibit.org, attaching a copy of the bank transfer receipt.

You can become an ordinary NIBIT member with an annual fee of € 50,00

ORGANISING SECRETARIAT

Acheloís - Professional Congress Organiser
Via Larga 8 - 20122 Milano
Tel. 02 5006 3031
e-mail: elena.delboca@achelois.eu

ACHELOÍS
PROFESSIONAL CONGRESS ORGANISER

CALL FOR ABSTRACT

All participants are encouraged to submit an abstract in English.

The abstracts will be reviewed by the Scientific Committee and selected for oral or poster presentation.

When submitting the abstract, presenting authors must select one of the following topics:

- Myeloid cells in cancer
- Uncovering the molecular interactions within the tumor microenvironment
- B and T cells in cancer
- AI in immune oncology from research to clinic
- Empowering immune cells for adoptive cell therapy
  Immunotherapy. Where we are and where we are going
- New targets in immune-oncology

The abstract should respect the following guidelines:

- The abstract must be submitted in English.
- Abstract title should be max 250 characters (spaces included) and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries
- should follow. One of the authors must be flagged as "Presenting author".
- Abstracts should be organized under the headings:
- Introduction
- Methods
- Results
- Conclusions
- Tables and figures can be uploaded as a separate file (JPG, max 1 page)
- The online abstract submission procedure will not accept abstracts that exceed 500 words
- Abbreviations may be used if standard or if spelled out and defined at the first use.
- Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. "generic (Commercial ®)"

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for the oral or poster presentation.

Please note that submitting an abstract does not constitute registration for the meeting.

To submit your abstract please access the link here